Results 211 to 220 of about 34,140,631 (244)

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou, Christoforos K. Travlos, Lucas Lage Marinho, Thomas A. Mavrakanas, João Pedro Ferreira, Abhinav Sharma   +5 more
wiley   +1 more source

Improvement of Chronic Spontaneous Urticaria After Glucagon-Like Peptide 1 Receptor Agonist Therapy: Report of Two Cases. [PDF]

Dermatol Ther (Heidelb)
Kwiek B, Sieczych J, Łukowska K, Ambroziak M.   +3 more
europepmc   +1 more source

Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction‐Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open‐Label Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Type 2 diabetes drives the progression of metabolic dysfunction‐associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium–glucose cotransporter 2 (SGLT2) inhibitor to a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), improves liver histology in adults with biopsy‐proven MASH and type 2 ...
Teruki Miyake, Osamu Yoshida, Shinya Furukawa, Masashi Hirooka, Masanori Abe, Yoshio Tokumoto, Ayumi Kanamoto, Takao Watanabe, Ryo Yano, Yuki Okazaki, Atsushi Yukimoto, Yoshiko Nakamura, Eiji Takeshita, Teru Kumagi, Yoichi Hiasa   +14 more
wiley   +1 more source

Consumer Food Purchases After Glucagon-Like Peptide-1 Receptor Agonist Initiation.

JAMA Netw Open
Sørensen KK, Møller FT, Yazdanfard PDW, Hasselbalch R, Kragholm KH, Andersen MP, Torp-Pedersen C.   +6 more
europepmc   +1 more source

Glucagon like peptide-1 receptor agonist therapy and long-term renal outcomes after radical nephrectomy: a propensity-matched cohort analysis. [PDF]

Int Urol Nephrol
Ahmad NB, Kassim A, Manivasagam SS, Raman JD.   +3 more
europepmc   +1 more source

Association of Lipid Ratios With Cardiovascular Outcomes in Type 2 Diabetes: A Population Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To identify low‐ and high‐risk intervals for major adverse cardiovascular events (MACE) and all‐cause mortality according to lipid ratios in adults with Type 2 diabetes mellitus (T2DM), stratified by sex. Materials and Methods We used primary care electronic health records from the Spanish National Health Service including 303 199 adults ...
Enrique Carretero‐Anibarro, Jose Antonio Quesada, Manuel A. Ruiz‐Quintero, Didac Mauricio, Kamlesh Khunti, Domingo Orozco‐Beltrán   +5 more
wiley   +1 more source

Effects of Glucagon-Like Peptide-1 Receptor Agonist on Bone Metabolism and the Expression of Insulin Receptor Substrate 1 in an Osteoporotic Rat Model. [PDF]

Int J Endocrinol
Ye Y, He YL, He J, Yang DY, Xia N.
europepmc   +1 more source

Dietary Soybean vs. Palm Oils Differ in Effects on Liver Fat in Adults With MAFLD: A 16‐Week, Double‐Masked, Randomized Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Dietary linoleic acid (LA)‐rich oils reduce liver fat in healthy adults who are not otherwise undergoing weight loss strategies. Effects on the liver fat in adults with fatty liver disease are unknown. Objective The objective of this randomized double‐masked controlled trial was to compare the effects of a dietary soybean oil (SO ...
Martha A. Belury, Rachel M. Cole, Ai Ni, Arunark Kolipaka, Manjunathan Nanjappa, Kristin Thompson, Ali Kalhori, Stephan Zarich, Rolando E. Choriego, Rafael Jimenez‐Flores, Na Li   +10 more
wiley   +1 more source

Antecedent glucagon-like peptide-1 receptor agonist use and risk of sepsis-induced cardiomyopathy in type 2 diabetes: a United States real-world active-comparator cohort study. [PDF]

Front Pharmacol
Wu JY, Lee KW, Huang SC, Chang HY, Lin YM.   +4 more
europepmc   +1 more source

Apelin/APJ Signalling as a Potential Complementary Target for Glucagon-like Peptide-1 Receptor Agonist Therapy in Heart Failure. [PDF]

Card Fail Rev
Alfonso DM.
europepmc   +1 more source